Sera Prognostics (NASDAQ:SERA) Stock Price Down 0.5% – Here’s What Happened

Sera Prognostics, Inc. (NASDAQ:SERA)’s stock price was down 0.5% during trading on Wednesday . The stock traded as low as $4.09 and last traded at $4.19. Approximately 82,006 shares were traded during trading, a decline of 44% from the average daily volume of 146,420 shares. The stock had previously closed at $4.21.

Sera Prognostics Stock Down 0.5 %

The stock’s fifty day simple moving average is $6.26 and its two-hundred day simple moving average is $6.92. The firm has a market cap of $141.50 million, a PE ratio of -4.23 and a beta of 0.81.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, Director Joshua Phillips sold 12,710 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the sale, the director now directly owns 5 shares in the company, valued at approximately $37. This trade represents a 99.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Benjamin Jackson sold 13,272 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.42, for a total transaction of $98,478.24. Following the completion of the transaction, the general counsel now owns 128,473 shares in the company, valued at approximately $953,269.66. This represents a 9.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,615 shares of company stock valued at $462,947 in the last ninety days. 15.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently made changes to their positions in SERA. Barclays PLC lifted its position in Sera Prognostics by 321.6% in the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after acquiring an additional 30,093 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Sera Prognostics by 7,357.8% in the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock worth $6,902,000 after purchasing an additional 873,002 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Sera Prognostics by 8.8% during the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after buying an additional 34,479 shares during the last quarter. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.